Inozyme Pharma to be Acquired by BioMarin in $270 Million Deal
Deal News | May 19, 2025 | Goodwins
Inozyme Pharma, a clinical-stage biopharmaceutical company specializing in therapies targeting the PPi-Adenosine Pathway, is set to be acquired by BioMarin Pharmaceutical for approximately $270 million. The acquisition has been approved by the Boards of Directors of both firms and is anticipated to conclude in the third quarter of 2025, pending regulatory approval. This acquisition will enhance BioMarin's portfolio, including the addition of INZ-701, a therapy in late-stage development for treating ENPP1 Deficiency. Goodwin's life sciences team, led by Rachael Bushey and supported by numerous legal professionals, represented Inozyme in this strategic transaction.
Sectors
- Biopharmaceutical
- Pharmaceutical
- Healthcare
- Legal Services
Geography
- United States – Inozyme Pharma is based in Boston, and the acquisition involves major U.S.-based companies.
Industry
- Biopharmaceutical – Inozyme Pharma is a clinical-stage biopharmaceutical company focused on developing treatments targeting the PPi-Adenosine Pathway, which is key to treating several severe diseases.
- Pharmaceutical – BioMarin Pharmaceutical Inc. operates within this sector, focusing on the acquisition of Inozyme Pharma to bolster its offerings in enzyme replacement therapies.
- Healthcare – The acquisition falls within the healthcare industry as it involves the development and expansion of treatment options for genetic conditions.
- Legal Services – Goodwin, a law firm, played a crucial role in advising Inozyme Pharma during the acquisition process.
Financials
- 270,000,000 – Total acquisition consideration in the all-cash transaction for Inozyme Pharma by BioMarin.
- 4.00 – Price per share in the acquisition of Inozyme Pharma.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Inozyme Pharma, Inc. | Target Company | Company | A clinical-stage biopharmaceutical company based in Boston focusing on therapies targeting the PPi-Adenosine Pathway. |
| BioMarin Pharmaceutical Inc. | Bidding Company | Company | A pharmaceutical company acquiring Inozyme to enhance its enzyme therapies portfolio. |
| Goodwin | Legal Advisor | Company | A law firm representing Inozyme Pharma in the acquisition process. |